Feasibility of Biodynamic Imaging for Predicting Effect of Gemcitabine and Nab-paclitaxel on Metastatic Adenocarcinoma of the Pancreas
B
Bert O'Neil, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this study is to determine if you can use an assay on tumor samples to see different patterns in response to the same chemotherapy treatment.
Description
The purpose of this study is to examine the feasibility of using biodynamic imaging (BDI) as a chemosensitivity assay on fresh tumor samples obtained by core needle biopsy from patients planned to receive routine care gemcitabine and nab-paclitaxel for treatment of metastatic adenocarcinoma of the pancreas.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Metastatic Adenocarcinoma of the Pancreas
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
26 Apr 2024.
Study ID: 1405049285 (IUCRO-0479)
